Dupont Nutrition and Health (Us) Enters into An Agreement with Lonza Specialty Ingredients (Switzerland) to Manufacture and Supply Care4u 2’-Fl

Care4u 2’-FL is a human milk oligosaccharide (HMO). HMOs are the third-most-abundant solid component of breast milk that promote infant health by supporting digestion, building immunity, and cognitive development through changes to the microbiome. Commercially produced HMOs such as CARE4u can provide some of the health benefits of the HMOs present in human milk, helping to close an important gap between human milk and infant formula.

MarketsandMarkets™ viewpoint:

Lonza has expertise in science and biotechnology and is a provider of solutions to the global healthcare, pharmaceuticals, nutrition, and personal care industries. It is also technologically equipped and has a comprehensive portfolio of proprietary nutritional ingredients. DuPont is a global innovation leader with technology-based materials, ingredients, and solutions that help in the transformation of industries. Through this collaboration, DuPont aims to enhance its business by providing consumer health and wellness products. The collaboration of DuPont with Lonza will also assist the former in obtaining a high-quality and reliable manufacturing supply chain. Lonza aims to develop and manufacture superior-quality human milk oligosaccharides.

Impact of collaboration

With the increase in world population, there is likely an increase in the demand for nutrition products, including HMOs for infant formula. The collaboration would help both the companies in providing superior-quality Care4u 2’-FL HMOs and in strengthening their position in the market with the product.

The figure below shows the market opportunity in the infant formula ingredients market. The infant formula ingredients market in Asia Pacific was the largest in 2016, and it is projected to grow at the highest CAGR during the forecast period. The major driver for the growth of the infant formula ingredients market in the region is the high consumption of infant formulas from emerging economies such as India and China.

FIGURE 1  INFANT FORMULA INGREDIENTS MARKET FORECAST TO 2022

INFANT FORMULA INGREDIENTS MARKET FORECAST TO 2022

e – Estimated; p – Projected
Source: MarketsandMarkets™ Analysis

Top Competitors:

Some of the major competitors in the infant formula ingredients market are AAK AB (Sweden), Fonterra Co-operative Group Limited (New Zealand), Carbery Food Ingredients Limited (Ireland), Royal FrieslandCampina N.V. (Netherlands), Sachsenmilch Leppersdorf GmbH (Germany), BASF SE (Germany), Koninklijke DSM N.V. (Netherlands), Arla Foods Amba (Denmark), Chr. Hansen Holdings A/S (Denmark), Kerry Group plc (Ireland), Lactalis Ingredients (France), Glanbia plc (Ireland), and Vitablend Nederland B.V. (Netherlands).

Conclusion:

The collaboration of Lonza and DuPont is likely to result in a high-quality supply chain of significant volume, which would be able to provide functional human milk oligosaccharides for the global market. It would also help both the companies in gaining a competitive edge by gaining a stronger market position by providing superior quality.

Leave a comment

Your email address will not be published. Required fields are marked *